Harish Shantharam Net Worth

What's Harish Shantharam's mailing address?

Harish's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7601 DUMBARTON CIRCLE, FREMONT, CA, 94555.

Insiders trading at Cymabay Therapeutics Inc

Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster és Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.

What does Cymabay Therapeutics Inc do?

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.

Cymabay Therapeutics Inc executives and stock owners

Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include:

• Sujal Shah,
  President, Chief Executive Officer, Director
• Charles McWherter,
  Senior Vice President, Chief Scientific Officer
• Klara Dickinson,
  Chief Regulatory and Compliance Officer
• Daniel Menold,
  Vice President - Finance
• Sujal A. Shah,
  Pres, CEO & Director
• Dr. Charles A. McWherter Ph.D.,
  Chief Scientific Officer
• Paul T. Quinlan,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Robert Wills,
  Independent Chairman of the Board
• Kurt von Emster,
  Independent Director
• Paul Truex,
  Independent Director
• Caroline Loewy,
  Independent Director
• Dr. Dennis D. Kim M.B.A., M.D., MBA,
  Chief Medical Officer
• Becki Filice,
  Sr. VP of Portfolio & Product Leadership
• Klara A. Dickinson-Eason,
  Chief Regulatory & Quality Assurance Officer
• Dr. Robert L. Martin,
  Sr. VP of Manufacturing & Nonclinical Devel.
• Patrick J. O'Mara,
  Sr. VP of Bus. Devel.
• Ken Boehm,
  Sr. VP of HR
• Daniel Menold,
  VP of Fin.
• Evan A. Stein,
  Director
• Robert F. Booth,
  Director
• Carl Goldfischer,
  Director
• Pol F Boudes,
  Chief Medical Officer
• Robert J. Weiland,
  Director
• Kirk Rosemark,
  V.P. Regulatory & Quality
• Wart Harold Van,
  President and CEO
• Emster Kurt Von,
  Director
• Thomas G Wiggans,
  
• Paul T Quinlan,
  General Counsel
• Eric Lefebvre,
  
• Harish Shantharam,
  Chief Financial Officer
• Lewis J Stuart,
  Chief Commercial Officer
• Patrick J. O Mara,
  VP, Business Development
• Robert L. Martin,
  Sr. Vice President
• Capital Advisors Llc Aghaza...,
  
• Edward Penhoet,
  Director
• Louis G Lange,
  Director
• Hari Kumar,
  Director
• Janet Dorling,
  
• Dennis D Kim,
  Chief Medical Officer